GlucoTrack
GCTK
8 hedge funds and large institutions have $594K invested in GlucoTrack in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 4 → 8 (+4)
0% more ownership
Funds ownership: 0% → 0% (+0%)
20% less capital invested
Capital invested by funds: $743K → $594K (-$149K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boston Financial Management
Boston,
Massachusetts
|
+$16.2K |
| 2 |
CHP
Cable Hill Partners
Portland,
Oregon
|
+$10.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.98K |
| 4 |
AWM
Accurate Wealth Management
Wesley Chapel,
Florida
|
+$7.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$8.98K |
GCTK Hedge Fund Activity: Q3 2023 in Review
8 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q3 2023, worth a combined $594K — down 20% from $743K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GCTK positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Boston Financial Management, opening a new position worth an estimated $16.2K. The largest seller was Sabby Management, cutting an estimated $8.98K.
- 8 institutional investors held GlucoTrack (GCTK) as of Q3 2023, up from 4 in Q2 2023.
- Funds reported $594K of GlucoTrack stock for Q3 2023, down 20% quarter-over-quarter.
- 4 funds opened new GlucoTrack positions in Q3 2023 and 0 closed out, a net change of +4 holders.
- The largest GlucoTrack buyer in Q3 2023 was Boston Financial Management, an estimated $16.2K added.
- The largest GlucoTrack seller in Q3 2023 was Sabby Management, an estimated $8.98K sold.
Based on aggregated 13F filings for Q3 2023.